Boehringer Ingelheim To Boost Cancer Immunology Portfolio with Novel Cancer Vaccines
By buying AMAL, Boehringer Ingelheim plans to develop new therapies by combining assets from its cancer immunology portfolio with the biotech’s KISIMA immunization platform, the German pharma’s head of cancer immunology business development tells Scrip.
You may also be interested in...
The German group is investing heavily in R&D and the continued strong performance of products like Spiriva and Pradaxa is helping to pay for future innovation.
Following in the wake of Merck & Co's acquisition of VelosBio, the German major is spending big to get hold of the Swiss oncology biotech NBE-Therapeutics which is also targeting the ROR1 protein.
The German pharma’s top business development execs explain how they balance IO and targeted cancer therapy in their portfolio, views on major M&A and how to make deals during a global pandemic.